Super Tadalista Tablets (Tadalafil and Dapoxetine Combination Tablets)

Super Tadalista (Tadalafil Dapoxetine Tablets)
© The Swiss Pharmacy
Super Tadalista (Tadalafil Dapoxetine Tablets) is a combination
medication consisting of Tadalafil 20 mg and Dapoxetine Hydrochloride 60
mg. It is a convenient solution for patients that require treatment for
Erectile Dysfunction (ED) as well as Premature Ejaculation (PE) at the
same time.
Tadalafil is used to treat erectile dysfunction, a condition in wherein a
man cannot get, or keep, a hard erect penis suitable for sexual activity.
Dapoxetine Hydrochloride is a treatment for premature ejaculation (PE) in
men 18 to 64 years old who have ejaculate within 2 minutes following
penetration and before the man wishes to as well as marked personal
distress and interpersonal difficulty as a result of premature ejaculation
and poor control over ejaculation.

Super Tadalista Tablets are
manufactured by Fortune
Healthcare Limited, India.

Tadalafil - Chemical Structure

Dapoxetine Hydrochloride - Chemical Structure

The active ingredients contained in
Super Tadalista tablets are Tadalafil and
Dapoxetine Hydrochloride.
Each Super Tadalista tablet contains 20
mg of Tadalafil and 60 mg of Dapoxetine
Hydrochloride.

Uses of Super Tadalista 80 mg tablets:
Super Tadalista is made up of two active ingredients (the substances that
produce the desired medical effects) Tadalafil and Dapoxetine
Hydrochloride.
Dapoxetine Hydrochloride is a treatment for men 18 to 64 years old with
frequent premature ejaculation (PE), which troubles the man and affects
the relationship with his sexual partner. PE is a common sexual disorder in
which ejaculation happens with minimal sexual stimulation before, on, or
shortly after penetration, and before the man wishes it.
Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor used for the treatment
of erectile dysfunction in adult males. In order for Tadalafil to be effective
for the treatment of erectile dysfunction, sexual stimulation is required.

Recommended Adult Dosage
The dose of
Super Tadalista (Tadalafil Dapoxetine Tablets) is one
80 mg tablet taken approximately one to three hours
before sexual activity with at least one full glass of water.
Tablets must be swallowed whole.
Do not take more than 1 tablet in any 24 hour period. At
least 24 hours must pass since your last dose.

Contraindications
➔
Super Tadalista is contraindicated in patients with a known
hypersensitivity to Tadalafil, Dapoxetine Hydrochloride or any
component of the tablet.
➔
Patients with significant pathological cardiac conditions, conduction
abnormalities, significant ischemic heart disease or significant valvular
disease.
➔
Administration of Super Tadalista to patients using any form of organic
nitrate is contraindicated. Tadalafil (Super Tadalista) has been shown to
potentiate the hypotensive effect of nitrates.
➔
Administration of this medicine along with guanylate cyclase (GC)
stimulators, such as Riociguat is contraindicated.

Contraindications
➔
Super Tadalista is contraindicated for concomitant treatment with monoamine
oxidase inhibitors (MAOIs), or within 14 days of discontinuing treatment with an
MAOI. Similarly, an MAOI should not be administered within 7 days after Super
Tadalista has been discontinued.
➔
Concomitant treatment with Thioridazine, or within 14 days of discontinuing
treatment with Thioridazine. Similarly, Thioridazine should not be administered
within 7 days after Super Tadalista has been discontinued
➔
Concomitant treatment with serotonin reuptake inhibitors or other
medicinal/herbal products with serotonergic effects [e.g., L-tryptophan, Triptans,
Tramadol, Linezolid, Lithium, St. John's Wort ] or within 14 days of
discontinuing treatment with these medicinal/herbal products is contraindicated.

Contraindications
➔
Super Tadalista is contraindicated for simultaneous
treatment with potent CYP3A4 inhibitors such as
Ketoconazole, Itraconazole, Ritonavir, Saquinavir,
Telithromycin, Nefazodone, Nelfinavir, Atazanavir, etc.
➔
Super Tadalista is contraindicated in patients with
moderate and severe hepatic impairment.

Storage Instructions
have to be stored at controlled room temperature
i.e. from 20°C to 25°C (68°F to 77°F) with
excursions permitted between 15° to 30°C (59°
to 86°F).
Keep this as well as all other medicines away
from children and pets.

Warnings
Patients should not use Super Tadalista if sex is inadvisable due to
cardiovascular status.
Use of Super Tadalista with alpha-blockers, antihypertensives or substantial
amounts of alcohol (5 units or greater) could lead to hypotension.
Patients should not use Super Tadalista if sex is inadvisable due to
cardiovascular status.
Use of Super Tadalista with alpha-blockers, antihypertensives or substantial
amounts of alcohol (5 units or greater) may lead to hypotension
Super Tadalista is not recommended in combination with alpha-blockers for the
treatment of BPH because efficacy of the combination has not been adequately
studied and because of the risk of blood pressure lowering.

Warnings
Caution is advised when Super Tadalista is used as a treatment for ED in men
taking alpha-blockers.
Patients should seek emergency treatment if an erection lasts for greater than
4 hours. Use Super Tadalista with caution in patients predisposed to priapism.
Patients should stop Super Tadalista and seek medical care if a sudden loss of
vision occurs in one or both eyes, which could be a sign of non-arteritic
anterior ischemic optic neuropathy (NAION).
Super Tadalista should be used with caution, and only when the anticipated
benefits outweigh the risks, in patients with a history of NAION. Patients with
a “crowded” optic disc may also be at an increased risk of NAION Patients
should stop Super Tadalista and seek prompt medical attention in the event of
sudden decrease or loss of hearing.

Warnings
Super Tadalista is only indicated in men with PE along with ED.
Patients must be advised not to use Tadalafil and Dapoxetine tablets in
combination with recreational drugs.
Recreational drugs with serotonergic activity like ketamine, methylenedioxy-
methamphetamine (MDMA) and lysergic acid diethylamide (LSD) may lead to
potentially serious reactions if combined with Super Tadalista tablets. These
adverse reactions include, but are not limited to, arrhythmia, hyperthermia,
and serotonin syndrome.
Combining alcohol with Super Tadalista may increase alcohol-related
neurocognitive effects and may also enhance neurocardiogenic adverse events
such as syncope, thereby increasing the risk of accidental injury.
Hence patients must be advised to avoid alcohol while taking Super Tadalista.

Warnings
The number and percentage of patients with syncope (characterized as loss of
consciousness) was greater in Dapoxetine-treated subjects than in those who were
treated with placebo during clinical trials. Possibly prodromal symptoms such as
nausea, dizziness/light-headedness, and diaphoresis were reported more
frequently among patients treated with Dapoxetine , a constituent of this medicine
compared to placebo.
The risk of adverse cardiovascular outcomes from syncope (cardiac syncope and
syncope from other causes) is increased in patients with underlying structural
cardiovascular disease.
An orthostatic test should be performed before initiating therapy. In case of a
history of documented or suspected orthostatic reaction, treatment with Super
Tadalista should be avoided.

Warnings
Caution is advised in all patients concomitantly treated with moderate CYP3A4 inhibitors.
Unless the patient is known to be a CYP2D6 extensive metaboliser, caution is advised when
used concomitantly with moderate CYP3A4 inhibitors.
Caution is advised in patients taking potent CYP2D6 inhibitors or in patients known to be
of CYP2D6 poor metaboliser genotype, as this may increase exposure levels, which may
result in a higher incidence and severity of dose dependent adverse events.
SSRIs like Dapoxetine, a constituent of this medication have been shown to increase the
risk compared to placebo of suicidal thinking and suicidality in short-term studies in
children and adolescents with Major Depressive Disorder and other psychiatric disorders.
Super Tadalista should not be used in patients with a history of mania/hypomania or
bipolar disorder and should be discontinued in any patient who develops symptoms of
these disorders. Due to the potential of SSRIs to lower the seizure threshold, Super
Tadalista should be discontinued in any patient who develops seizures and avoided in
patients with unstable epilepsy. Patients with controlled epilepsy should be carefully
monitored.

Warnings
Super Tadalista should not be used in individuals below 18 years of age or
patients with Co-morbid depression and psychiatric disorders.
Men with underlying signs and symptoms of depression should be
evaluated prior to treatment with Super Tadalista to rule out undiagnosed
depressive disorders. Concomitant treatment of Dapoxetine with
antidepressants, including SSRIs and SNRIs, is contraindicated.
There have been reports of bleeding abnormalities with SSRIs. Caution is
advised in patients taking Super Tadalista, particularly in concomitant use
with medicinal products known to affect platelet function, as well as in
patients with a history of bleeding or coagulation disorders. Super
Tadalista is not recommended for use in patients with renal impairment.

Possible Super Tadalista Side Effects
The most common side effects of Super Tadalista
(Tadalafil Dapoxetine Tablets) are headache,
dyspepsia, back pain, myalgia, nasal congestion,
flushing, pain in limb, dizziness, nausea, diarrhoea,
insomnia, somnolence, fatigue, abdominal pain and
anxiety.

Super Tadalista Overdosage
Super Tadalista overdose symptoms are a combination of the overdose
symptoms of Tadalafil and Dapoxetine Hydrochloride and can include
chest pain, nausea, irregular heartbeat, feeling light-headed or fainting,
somnolence, gastrointestinal disturbances such as nausea and vomiting,
tachycardia, tremor, agitation and dizziness.
In cases of overdose, standard supportive measures should be taken as
necessary. Due to high protein binding and large volume of distribution
of Dapoxetine Hydrochloride, forced diuresis, dialysis, hemoperfusion
and exchange transfusion are unlikely to be of benefit. Hemodialysis
contributes negligibly to Tadalafil elimination. No specific antidotes for
Super Tadalista (Tadalafil Dapoxetine Tablets) are presently known.

Super Tadalista During Pregnancy
Super Tadalista is a combination medication containing Tadalafil
and Dapoxetine Hydrochloride. Tadalafil has been classified by the
US FDA as Pregnancy Category B. Dapoxetine HCl has been
classified by the US FDA as Pregnancy Category C. Super Tadalista
is not indicated for use by women.
There is no evidence to suggest that Dapoxetine exposure has an
effect on a partner's pregnancy based on limited observational data
obtained from the clinical trial database. There are no adequate and
well-controlled studies of Tadalafil or Dapoxetine conducted in
pregnant women.

We also have in stock Super Vidalista Tablets which
are used to treat the same indications

Super Tadalista Tablets are manufactured
by Fortune Healthcare Limited, India.
For More details Click Here

Super Tadalista Tablets (Tadalafil and Dapoxetine Combination Tablets)

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Super Tadalista Tablets (Tadalafil and Dapoxetine Combination Tablets)

Similar to Super Tadalista Tablets (Tadalafil and Dapoxetine Combination Tablets) (20)

More from The Swiss Pharmacy

More from The Swiss Pharmacy (20)

Recently uploaded

Recently uploaded (20)

Super Tadalista Tablets (Tadalafil and Dapoxetine Combination Tablets)